The stated objective of the Fund is to achieve long-term capital growth.
Name | % Net Assets |
---|---|
Novozymes | 8.5% |
Neopost | 8.2% |
Novo Nordisk | 7.9% |
DnB NOR | 6.7% |
Reed Elsevier | 6.3% |
Vopak | 4.9% |
CGGVeritas | 4.9% |
Euler | 4.6% |
Syngenta | 4.6% |
Dassault Systemes | 4.3% |
Key | % Net Assets |
---|---|
Novozymes | 8.5% |
Neopost | 8.2% |
Novo Nordisk | 7.9% |
DnB NOR | 6.7% |
Other | 68.7% |
Date | 21-Nov-2024 |
---|---|
NAV | 2,910.48p |
Currency | GBP |
Change | -2.47p |
% | -0.08% |
YTD change | -217.62p |
YTD % | -6.96% |
Fund Inception | 03/08/1987 |
---|---|
Fund Manager | n/a |
TER | 1.78 (31-Oct-2013) |
Minimum Investment | |
---|---|
Initial | £500 |
Additional | n/a |
Savings | £100 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.09 |
You are here: research